Zymeworks Inc. announced on April 21, 2025, the appointment of Sabeen Mekan, M.D., as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will play a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs.
Dr. Mekan brings 18 years of experience in hematology and oncology, spanning academic research, clinical practice, and biopharmaceutical industry development. Her prior roles include leadership positions at Gilead Sciences, Daiichi Sankyo U.S., and Bristol-Myers Squibb, where she focused on global clinical development and immune-oncology.
This expanded senior clinical development team aims to enhance Zymeworks' focus on progressing its solid tumor portfolio while pursuing diversification into autoimmune and inflammatory diseases and hematological cancers. Dr. Mekan's expertise is expected to be instrumental in advancing the company's '5x5' programs and future product development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.